On this page
Hyperkalaemic periodic paralysis
This condition is characterised by sudden, temporary muscle weakness or paralysis, typically affecting skeletal muscles. It is caused by genetic changes in the SCN4A gene and usually becomes apparent in childhood, though severity can vary significantly.
Overview
Hyperkalaemic periodic paralysis (HyperPP) is a rare inherited disorder primarily affecting the skeletal muscles. Individuals with HyperPP experience episodes of muscle weakness or paralysis, which can range from mild to severe. These episodes are often triggered by factors that increase potassium levels in the blood, such as consuming high-potassium foods, fasting, or vigorous exercise [PMID:33678077]. The condition generally presents during childhood or adolescence and is lifelong, although the frequency and severity of attacks can sometimes decrease with age.
HyperPP is one of several types of periodic paralysis, a group of disorders that cause temporary muscle weakness. What distinguishes HyperPP is its association with elevated blood potassium (hyperkalaemia) during or just before an attack, although not every attack is accompanied by measurable hyperkalaemia. This condition is inherited in an autosomal dominant pattern, meaning a single altered copy of a specific gene is sufficient to cause the disorder.
Symptoms & clinical features
The primary symptom of HyperPP is episodic muscle weakness, which can vary widely in severity, from mild weakness to complete paralysis of affected muscles. These episodes typically last from minutes to several hours, but can occasionally persist for a day or longer. Attacks most often begin in early childhood, sometimes in infancy, and usually involve muscles of the limbs and trunk [PMID:33678077]. Muscles of the face, neck, and throat are generally spared, meaning speech and swallowing are usually unaffected.
Triggers for these episodes commonly include rest after exercise, consumption of potassium-rich foods, exposure to cold, emotional stress, or skipping meals [PMID:20301402]. Some individuals may also experience myotonia, which is a delayed relaxation of muscles after contraction. This can manifest as muscle stiffness, particularly after exercise or in cold temperatures, and may affect eyelid muscles, causing temporary difficulty opening the eyes.
Video: Genetics 101
Affected organs
Hyperkalaemic periodic paralysis predominantly affects the skeletal muscles, which are the voluntary muscles responsible for movement. These include the muscles of the arms, legs, and trunk. During an episode, the function of these muscles is temporarily impaired, leading to weakness or paralysis. The heart muscle (cardiac muscle) and smooth muscles (such as those in the digestive system) are not typically affected by this condition.
Risks & severity
The severity of HyperPP can vary considerably between individuals, even within the same family. Some people experience only mild, infrequent episodes of weakness, while others may have more frequent and debilitating attacks. The frequency of episodes is often highest in adolescence and young adulthood, with some individuals finding that attacks become less severe or less frequent later in life. While episodes are typically transient, in rare cases, prolonged severe weakness can lead to fixed muscle weakness over time. The exact prevalence of HyperPP is not well established due to its rarity and potential for misdiagnosis.
There is a potential risk of respiratory muscle involvement in very severe attacks, though this is uncommon. It is important for individuals to be aware of their personal triggers and work with healthcare professionals to manage their condition effectively and minimise these risks.
Genetic causes
Hyperkalaemic periodic paralysis is caused by genetic changes (pathogenic variants) in the SCN4A gene. This gene provides instructions for making a protein component of a sodium channel. Sodium channels are pores in the cell membrane that regulate the flow of sodium ions into muscle cells. This ion movement is crucial for the electrical signals that cause muscles to contract.
In individuals with HyperPP, pathogenic variants in SCN4A lead to an altered sodium channel that does not close properly or closes too slowly after muscle contraction [PMID:20301402]. This dysfunctional channel allows sodium ions to leak into the muscle cell, which can disrupt the cell's electrical balance and make the muscle less able to contract effectively. This leads to the characteristic episodes of weakness and paralysis. Specifically, high potassium levels, or other triggers, can exacerbate this faulty channel function, leading to the temporary paralysis seen in HyperPP.
- SCN4A sodium voltage-gated channel alpha subunit 4
Inheritance pattern
Hyperkalaemic periodic paralysis is inherited in an autosomal dominant pattern. This means that an individual only needs one altered copy of the SCN4A gene to develop the condition. If a parent has HyperPP, there is a 50% chance with each pregnancy that their child will inherit the altered gene and therefore be affected. This pattern applies equally to male and female offspring.
Individuals who inherit the altered gene may experience symptoms with varying degrees of severity, even within the same family. In some cases, HyperPP can result from a new (de novo) genetic change that occurs for the first time in an individual with no family history of the condition. In such cases, the parents are unaffected, but the individual with HyperPP can then pass the condition on to their children.
Each child has a 50% chance of inheriting the pathogenic variant, regardless of sex.
Diagnosis & testing
Diagnosis of HyperPP typically begins with a clinical evaluation based on the characteristic symptoms of episodic muscle weakness, often linked to triggers and sometimes accompanied by elevated blood potassium levels. Clinical examination during an attack may reveal muscle weakness. Further investigations may include electromyography (EMG) to assess muscle electrical activity and blood tests to measure potassium levels during or between attacks.
Confirmation of HyperPP relies on genetic testing to identify a pathogenic variant in the SCN4A gene. Genetic testing for periodic paralysis, including HyperPP, is available through the NHS Genomic Medicine Service (GMS) under specific R-codes for neuromuscular disorders. Referrals for genetic testing are typically made by a neurologist or a clinical genetics specialist after an initial clinical assessment. A confirmed genetic diagnosis can help distinguish HyperPP from other forms of periodic paralysis or other conditions causing muscle weakness.
Management & lifestyle
Management of HyperPP focuses on preventing episodes of weakness and alleviating symptoms when they occur. Lifestyle modifications are often key, such as avoiding known triggers like high-potassium foods (e.g., bananas, potatoes, dried fruits), prolonged fasting, or strenuous exercise followed by rest. Regular, moderate exercise and frequent small meals can help maintain stable blood sugar and potassium levels. Some individuals may benefit from dietary advice from a dietitian to help manage their potassium intake.
Medication may be prescribed to help prevent attacks or reduce their severity. Diuretics, such as acetazolamide or hydrochlorothiazide, may be used to help lower blood potassium levels and prevent episodes. These medications should only be taken under the guidance of a healthcare professional. Individuals with HyperPP are typically managed by a neurologist, often in conjunction with a clinical geneticist, and may be referred to other specialists as needed through the NHS care pathway. Genetic counsellors can provide support and information regarding inheritance patterns and family planning.
UK care pathway
In the UK, individuals suspected of having Hyperkalaemic periodic paralysis are typically referred to specialist services within the NHS. This often starts with a neurologist who can assess symptoms and recommend initial investigations. If a genetic cause is suspected, referral to a Clinical Genetics service is appropriate. Genetic testing for HyperPP, specifically targeting the SCN4A gene, is available through the NHS Genomic Medicine Service (GMS) as part of national testing pathways for inherited neuromuscular disorders. Results from these tests can confirm a diagnosis and inform ongoing management. Genetic counsellors play a vital role in explaining the genetic basis of the condition, inheritance patterns, and implications for family members.
Frequently asked questions
What triggers an episode of muscle weakness?
Common triggers for HyperPP episodes include resting after exercise, eating foods high in potassium, fasting, stress, and exposure to cold. Understanding and avoiding personal triggers can help reduce the frequency of attacks.
Can Hyperkalaemic periodic paralysis be cured?
Currently, there is no cure for HyperPP, but the condition can be managed effectively. Treatments focus on preventing episodes of weakness and alleviating symptoms when they occur, often through lifestyle adjustments and sometimes medication.
Will my children inherit Hyperkalaemic periodic paralysis?
Hyperkalaemic periodic paralysis is inherited in an autosomal dominant pattern. If you have the condition, each of your children has a 50% chance of inheriting the altered gene and potentially developing the condition. Genetic counselling can provide more detailed information and support for family planning.
Are there any long-term effects of Hyperkalaemic periodic paralysis?
Most episodes of weakness are temporary and resolve completely. However, in some rare cases, frequent or severe attacks can lead to some persistent muscle weakness over many years. Regular follow-up with a neurologist helps monitor for any long-term effects.
Is Hyperkalaemic periodic paralysis the same as other types of periodic paralysis?
No, Hyperkalaemic periodic paralysis is distinct from other forms, such as hypokalaemic periodic paralysis. The key difference lies in how blood potassium levels change during attacks and the specific genes involved, although some genes like SCN4A can be associated with multiple forms.
References
- Yong SL, Sin TH, Tang EB. Hyperkalaemic periodic paralysis in pregnancy. BMJ case reports. 2018. PMID: 29866669
- Ashwood EM, Russell WJ, Burrow DD. Hyperkalaemic periodic paralysis and anaesthesia. Anaesthesia. 1992. PMID: 1626667
- Cox JH. Hyperkalaemic periodic paralysis: diagnosing the disease in the headlines. Equine veterinary journal. 1993. PMID: 8508741
- Tan SV, Suetterlin K, Männikkö R. In vivo assessment of interictal sarcolemmal membrane properties in hypokalaemic and hyperkalaemic periodic paralysis. Clinical neurophysiology : official journal of the International Federation of Clinical Neurophysiology. 2020. PMID: 32066100
- Meyer TS, Fedde MR, Cox JH. Hyperkalaemic periodic paralysis in horses: a review. Equine veterinary journal. 1999. PMID: 10505950
- Naylor JM, Jones V, Berry SL. Clinical syndrome and diagnosis of hyperkalaemic periodic paralysis in quarter horses. Equine veterinary journal. 1993. PMID: 8508753
- ALLSOP JL, GOULSTON K, JOHNSTON C. FAMILIAL HYPERKALAEMIC PERIODIC PARALYSIS. Australasian annals of medicine. 1964. PMID: 14122202
- Stunnenberg BC, Merkus EC, Raaphorst J. N-of-1 trial of salbutamol in hyperkalaemic periodic paralysis. Journal of neurology, neurosurgery, and psychiatry. 2021. PMID: 34112717